|
Applied NeuroSolutions’ Founding Scientist, Dr. Peter Davies, to Participate on an Expert Panel on Alzheimer’s Disease Hosted by Credit Suisse
Vernon Hills, IL December 12, 2007 – Applied NeuroSolutions, Inc. (OTC BB:APNS, www.appliedneurosolutions.com), a Company focused on the development of an integrated portfolio of products for the treatment and diagnosis of Alzheimer’s disease (AD), today announced Dr. Peter Davies, its founding scientist, and the Judith and Burton P. Resnick Professor of Alzheimer’s Disease Research at Albert Einstein College of Medicine (AECOM), will be participating on an expert panel on Alzheimer’s disease hosted by Credit Suisse on December 14, 2007 at 10:00 a.m. eastern time.
Dr. Davies will provide opening remarks on the Tau Hypothesis and Cell Cycle Theory as it relates to Alzheimer’s solutions, which will then be followed by a question and answer session.
Applied NeuroSolutions scientists’ and Dr. Davies’ work has focused on hyperphosphorylation of the neuronal protein tau. Hyperphosphorylated tau is the building block for the paired helical filaments that form the neurofibrillary tangles that are one of the two hallmark pathologies of AD. This tau-based approach is the basis of the Company’s development of diagnostic tests for early detection of AD, and in collaboration with Eli Lilly and Company, the development of tau-based novel AD therapeutic compounds.
About Applied NeuroSolutions:
Applied NeuroSolutions, Inc. (OTC BB:APNS - News) is developing diagnostics to detect Alzheimer's disease (AD) based on discoveries originating from the Albert Einstein College of Medicine and, in collaboration with Eli Lilly and Company, is developing novel therapeutic compounds to treat the progression of the disease. Applied NeuroSolutions is pursuing biomarkers that the company believes will aid in the development of effective AD treatments. Applied NeuroSolutions is focused on both a cerebrospinal fluid (CSF) diagnostic test and blood tests to detect AD at a very early stage. The CSF test can already differentiate AD patients from those with other diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect Alzheimer's disease. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be 30 million patients. For more information, visit www.appliedneurosolutions.com.
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.
Contact:
Applied NeuroSolutions 847-573-8000
Ellen Hoffing, President, CEO
David Ellison, CFO
|
